J Clin Pharmacol Ther. 2023;4(1):JCPT-04-1037 | Open Access
Yunmei Wang, Jiao Yang, Yanwei Shen, Xiang wang, Guangxi Wang and Jin Yang
Objective: We have observed in previous clinical studies: the predictive performance of TLR2 for endocrine resistance was higher in HER2-positive Breast Cancer (BCa) than in other hormone receptor-positive BCa cases so, what about TLR2 expression in triple positive breast cancer cell lines (BT474)? This research aimed to evaluate the expression and establishment of drug resistance model of TLR2 in ... Read more
RESEARCH ARTICLE Updated Mar 03, 2023 PDF
J Clin Pharmacol Ther. 2023;4(1):JCPT-04-1036 | Open Access
Rubin Zareski
Achievement of sustainable economic stability and growth in the last 15 years was influenced by the absence or inconsistence of structural reforms in the major world economies. Negative or zero growth trends in the country’s GDP have significantly affected the Pharma industries, forcing them to shift and/or reduce the costs in all horizontal areas of business, affecting among ... Read more
RESEARCH ARTICLE Updated Jan 28, 2023 PDF
J Clin Pharmacol Ther. 2022;3(2):JCPT-03-1035 | Open Access
Ferrara M, Trevisan G, Marinaro L, Accardo G, Fantino S, Alladio F, Drappero E, Tettoni M, De Vivo E, Ianniello A, De Nicolò A, D’AvolioA, Calcagno A and Bonora S
Background: Doravirine (DOR) and Rilpivirine (RPV) are the NNRTIs currently most used in the clinical setting, in dual and triple drug regimens (2DR and 3DR). Intracellular (IC) Pharmacokinetics (PK) of these drugs has not been fully elucidated. Our aim was to compare plasma PK and IC accumulation in real-life experienced patients (pts).
Methods: Pts on DOR- and RPV-including Antiretroviral (... Read more
SHORT COMMUNICATION Updated Dec 22, 2022 PDF
J Clin Pharmacol Ther. 2022;3(2):JCPT-03-1034 | Open Access
Yu Kyong Kim, Young-Sim Choi, Won Tae Jung, Kyu-Yeol Nam, Jae Seok Roh, Youn-Woong Choi, Sang-Min Cho, Do-Hyung Ki, Tae-Wan Kim, Hye J. Lee, Su Jeong, Min Kyu Park, Ha-Yeon Kim, Ji Hyeon Lee and Jun Gi Hwang
Purpose: Proton-pump inhibitors, such as rabeprazole, are prone to degradation in stomach acid. The use of Enteric-Coated (EC) forms minimizes this problem; however, these forms have slower onset time. The Pharmacokinetics (PK) and Pharmacodynamics (PD) of rabeprazole in a Fixed-Dose Combination (FDC) tablet with sodium bicarbonate, which was used to raise the intragastric pH, and in a conventional EC tablet ... Read more
RESEARCH ARTICLE Updated Dec 20, 2022 PDF
J Clin Pharmacol Ther. 2022;3(2):JCPT-03-1033 | Open Access
Oliva B, Gómez NA and Fernández JR
Cancer is a disease with high incidence. Other therapies as surgery and radiotherapy are also used in the treatment of this disease. However, the effect adverse and the metastasis limited the use of these therapies. Target anticancer Targeted cancer treatment is an attractive approach where drugs or other substances which targets specific molecules to block the growth and spread of ... Read more
RESEARCH ARTICLE Updated Dec 16, 2022 PDF